专利号:US-2002165207-A1 优先权日:2001-05-02 标题 :Compositions and methods for the treatment of diabetic neuropathy 发明人:ROSENBLOOM RICHARD 摘要:Compositions and a method for the treatment of diabetic neuropathy is disclosed. The compositions comprise a mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant, optionally formulated in a pharmaceutically acceptable carrier. This combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In addition, the compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is administered on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms of diabetic neuropathy, as well as at least some recovery of the damaged nerve tissues.
专利号:US-7914823-B2 优先权日:2000-12-21 标题 :Method and composition for the topical treatment of diabetic neuropathy 发明人:ROSENBLOOM RICHARD ALLEN 权利人:PROPHASE LABS INC 摘要:A method and composition for the treatment of diabetic neuropathy is disclosed. The composition comprises a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant formulated in a pharmaceutically acceptable carrier. It has been found that this combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In view of the consensus in the art that effective combinations of various active agents have not been demonstrated to be effective for the treatment of diabetic neuropathy, the present invention provides a surprising and unexpected effect. In addition, the topical compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the topical administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is topically administered to the areas of the body that have been adversely affected by the diabetic neuropathy on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms and at least some recovery of the damaged nerve tissues.
1: Hou GR, Zeng K, Lan HM, Wang Q. Juglanin ameliorates UVB induced skin carcinogenesis via anti inflammatory and proapoptotic effects in vivo and in vitro. Int J Mol Med. 2018 Jul;42(1):41-52. doi: 10.3892/ijmm.2018.3601. Epub 2018 Mar 29. doi: 10.3892/ijmm.2018.3554. Epub 2018 Mar 9. 3: Makule E, Schmidt TJ, Heilmann J, Kraus B. Diarylheptanoid Glycosides of Morella salicifolia Bark. Molecules. 2017 Dec 19;22(12). pii: E2266. doi: 10.3390/molecules22122266. doi: 10.18632/oncotarget.21317. eCollection 2017 Nov 7. 5: Zhang FX, Xu RS. Juglanin ameliorates LPS-induced neuroinflammation in animal models of Parkinson's disease and cell culture via inactivating TLR4/NF-κB pathway. Biomed Pharmacother. 2018 Jan;97:1011-1019. doi: 10.1016/j.biopha.2017.08.132. Epub 2017 Nov 8. doi: 10.1016/j.bbrc.2017.09.132. Epub 2017 Sep 25. pii: E1100. doi: 10.3390/molecules22071100. doi: 10.1080/10286020.2017.1295228. Epub 2017 Mar 17. doi: 10.1016/j.biopha.2016.11.030. Epub 2016 Nov 26. doi: 10.1016/j.biopha.2016.04.013. Epub 2016 Apr 23. doi: 10.1016/j.jphotobiol.2015.10.016. Epub 2015 Oct 23. doi: 10.1007/s11418-014-0817-0. Epub 2014 Feb 12. doi: 10.1055/s-0033-1360277. Epub 2014 Jan 23. doi: 10.1007/s12272-013-0307-z. Epub 2013 Nov 29. doi: 10.1016/j.jpba.2013.10.037. Epub 2013 Nov 7. doi: 10.1016/j.fitote.2013.10.007. Epub 2013 Oct 19. doi: 10.1021/np300212c. Epub 2012 Oct 15. Chinese. doi: 10.1007/s12272-011-0404-9. Epub 2011 May 5. doi: 10.1055/s-0030-1250609. Epub 2010 Dec 14.
合成参考文献
参考文献:10.2147/dddt.s250904 摘要:Liu J, Chen L, Zhang X, Pan L, Jiang L. The Protective Effects of Juglanin in Cerebral Ischemia Reduce Blood-Brain Barrier Permeability via Inhibition of VEGF/VEGFR2 Signaling. Drug Des Devel Ther. 2020;14():3165–75.